NCT05803811 is a NA clinical trial of Riboflavin in Quality of Life, sponsored by dsm-firmenich Switzerland AG.

Who is sponsoring NCT05803811?

NCT05803811 is sponsored by dsm-firmenich Switzerland AG.

What drugs are being tested in NCT05803811?

Interventions in NCT05803811: Riboflavin.

What condition does NCT05803811 study?

NCT05803811 studies Quality of Life.

Is NCT05803811 still recruiting?

NCT05803811 is currently completed. Last updated 17 January 2025.

Last reviewed 2025-01-17 · How we verify

NCT05803811

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Colon Delivered Vitamin B2 on Gut Microbiota and Related Health Biomarkers in Healthy Older Adults

Completed NA Last updated 17 January 2025

What this trial tests

NA trial testing Riboflavin in Quality of Life in 348 participants. Completed in 6 July 2023.

Timeline

12 December 2022

Primary endpoint
6 July 2023

6 July 2023

Quick facts

Lead sponsor	dsm-firmenich Switzerland AG
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	basic science
Enrollment	348
Start date	12 December 2022
Primary completion	6 July 2023
Estimated completion	6 July 2023
Sites	1 location across Ireland

Drugs / interventions tested

Riboflavin (RIBOFLAVIN) — full drug profile →

Conditions studied

Quality of Life — all drugs for Quality of Life →

Sponsor

dsm-firmenich Switzerland AG — full company profile →

Who can join

Adults 50 to 70, any sex, with Quality of Life. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this intervention study (clinical trial) is to investigate the effect of colon-delivered Riboflavin (vitamin B2) on the faecal microbial composition and diversity in older healthy subjects (50 -70 years of age)

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Microbial micronutrient sharing, gut redox balance and keystone taxa as a basis for a new perspective to solutions targeting health from the gut.
Steinert RE, Rehman A, Sadabad MS, Milanese A, et al · · 2025 · cited 8× · PMID 40090884 · DOI 10.1080/19490976.2025.2477816
Clinical Measurement of Transepidermal Water Loss.
Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148

Verify or expand the search:

Other trials of Riboflavin

Trials testing the same drug.

NCT05907850 — Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes · EARLY_PHASE1 · completed
NCT04232800 — Riboflavin for Glutamate Reduction in Alcohol Withdrawal · Phase 2 · unknown
NCT03432572 — Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets · EARLY_PHASE1 · completed
NCT03151096 — Pilot Evaluation of the Effect of Riboflavin Supplementation on Blood Pressure and Possible Effect Modification by the M · NA · terminated
NCT02863809 — Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit · Phase 1, PHASE2 · completed

Other recruiting trials for Quality of Life

Currently open trials in the same condition.

NCT07498959 — Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer · NA · recruiting
NCT07416448 — Neuroma-Associated Pain Management After Combat-Related Trauma in Ukraine · NA · recruiting
NCT07412379 — Predictive Factors for Functional and Quality of Life Decline in Patients >65 Years With a Gastrointestinal Tract Cancer · recruiting
NCT07380789 — Comprehensive Multicenter Study on the Management of Acute Pain Following Thoracic Combat-Related Trauma in Ukraine · NA · recruiting
NCT07280416 — Evolution of Insomnia During the First Year in Patients Newly Diagnosed With Cancer · recruiting

Other dsm-firmenich Switzerland AG trials

Trials by the same sponsor.

NCT06889779 — Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms · NA · recruiting
NCT06425081 — Investigating the Impact of Humiome B2 (Colon Delivered Riboflavin) and Riboflavin-overproducer Probiotic Strain Limosil · NA · completed
NCT06578455 — A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions · Phase 1 · completed
NCT06471023 — A Pharmacokinetic Study of Single Oral Doses of Six Different Vitamin C Product Forms · NA · completed
NCT05205785 — Human Milk Oligosaccharides (HMOs) for Irritable Bowel Syndrome (IBS) · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05803811 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by dsm-firmenich Switzerland AG
Last refreshed: 17 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05803811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing